Institute of Hematology & Hospital of Blood Diseases, State Key Laboratory of Experimental Hematology, Chinese Academy of Medical Sciences & Peking Union of Medical College, Tianjin, People's Republic of China.
Stem Cells Dev. 2010 Oct;19(10):1511-22. doi: 10.1089/scd.2009.0321.
Stem cells transplantation holds great promise for the treatment of ischemic diseases through functional revascularization. Umbilical cord-derived mesenchymal stem cells (UC-MSCs) are also an ideal candidate for cell-based bioengineering. Herein, we report on the development of a simple and effective protocol to isolate UC-MSCs, and confirm their endothelial potential both in vitro and in vivo. UC-MSCs were isolated by a novel explantation technique and induced to differentiate into endothelial-like cells. Then UC-MSCs were transplanted into ischemic mouse model and cultured on 3D gel/MMT-CS composite scaffolds. Morphological and proliferation assessments show that sufficient UC-MSCs can be generated during a relatively short culture period with explantation technique. Increased expression of endothelial-specific markers (KDR and vWF), and functional markers (ac-LDL uptake and UEA-1 binding), indicate that functional endothelial progenitor cells are induced after 9 days of in vitro culture. In an ischemic hindlimb mouse model, the ratio of ischemic/nonischemic limb perfusion 4 weeks after MSCs transplantation reached 0.84 +/- 0.09. The capillary density of this group was 2.57-fold greater than that of sham-injected mice (P < 0.05). Immunofluorescence and immunohistological analyses indicate that MSCs may act to salvage the ischemic tissue by incorporating into the local vasculature. In vitro, UC-MSCs were observed to incorporate into 3D gel/MMT-CS composite scaffolds, to secrete extracellular matrix, to remain viable, and to retain their proliferation capacity. In conclusion, UC-MSCs isolated by novel yet simple explantation technique are well suited for application in the development of novel stem cell-based revascularization therapies.
干细胞移植通过功能性再血管化为缺血性疾病的治疗带来了巨大的希望。脐带间充质干细胞(UC-MSCs)也是细胞基生物工程的理想候选物。在此,我们报告了一种简单有效的分离 UC-MSCs 的方案,并在体外和体内证实了其内皮潜能。通过一种新的组织块培养技术分离 UC-MSCs,并将其诱导分化为内皮样细胞。然后将 UC-MSCs 移植到缺血性小鼠模型中,并在 3D 凝胶/MMT-CS 复合支架上培养。形态学和增殖评估表明,组织块培养技术可以在相对较短的培养时间内产生足够数量的 UC-MSCs。内皮特异性标志物(KDR 和 vWF)和功能标志物(ac-LDL 摄取和 UEA-1 结合)的表达增加表明,在体外培养 9 天后可以诱导功能性内皮祖细胞。在缺血性后肢小鼠模型中,移植后 4 周时缺血/非缺血肢体灌注的比值达到 0.84 +/- 0.09。该组的毛细血管密度比假注射组高 2.57 倍(P < 0.05)。免疫荧光和免疫组织化学分析表明,MSCs 可能通过整合到局部血管系统来拯救缺血组织。在体外,观察到 UC-MSCs 整合到 3D 凝胶/MMT-CS 复合支架中,分泌细胞外基质,保持存活并保持增殖能力。总之,通过新颖而简单的组织块培养技术分离的 UC-MSCs 非常适合用于开发新型基于干细胞的血管生成治疗方法。
Mater Sci Eng C Mater Biol Appl. 2014-9-16
Stem Cell Res Ther. 2016-3-22
Prog Biomed Eng (Bristol). 2020-1
Stem Cell Res Ther. 2016-4-4